Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan
المؤلفون المشاركون
Takahashi, Shoko
Hiramatsu, Megumi
Hotta, Shinichi
Watanabe, Yukie
Suga, Osamu
Endo, Yutaka
Miyamori, Isamu
المصدر
International Journal of Hypertension
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-10-24
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Prospective postmarketing surveillance of Selara (eplerenone), a selective mineralocorticoid receptor antagonist, was performed to confirm its safety and efficacy for hypertension treatment in Japan.
The change in blood pressure after initiation of eplerenone treatment was also examined.
Patients with essential hypertension who were eplerenone-naïve were recruited regardless of the use of other antihypertensive drugs.
For examination of changes in blood pressure, patients were excluded if eplerenone was contraindicated or used off-label.
Patients received 50–100 mg of eplerenone once daily and were observed for 12 weeks.
No treatments including antihypertensive drugs were restricted during the surveillance period.
Across Japan, 3,166 patients were included for safety analysis.
The incidence of adverse drug reactions was 2.4%.
The major adverse drug reactions observed were hyperkalemia (0.6%), dizziness, renal impairment, and increased serum potassium (0.2% each).
The mean systolic blood pressure decreased from 152.1 ± 19.0 mmHg to 134.8 ± 15.2 mmHg at week 12, and the mean diastolic blood pressure decreased from 85.8 ± 13.7 mmHg to 77.7 ± 11.4 mmHg.
There were no significant new findings regarding the type or incidence of adverse reactions, and eplerenone had a clinically significant antihypertensive effect, leading to favorable blood pressure control.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Takahashi, Shoko& Hiramatsu, Megumi& Hotta, Shinichi& Watanabe, Yukie& Suga, Osamu& Endo, Yutaka…[et al.]. 2016. Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan. International Journal of Hypertension،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1106234
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Takahashi, Shoko…[et al.]. Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan. International Journal of Hypertension No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1106234
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Takahashi, Shoko& Hiramatsu, Megumi& Hotta, Shinichi& Watanabe, Yukie& Suga, Osamu& Endo, Yutaka…[et al.]. Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan. International Journal of Hypertension. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1106234
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1106234
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر